HOUSTON, TX — November 5, 2025 — Leads & Copy — Marker Therapeutics Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company, has appointed Kathryn Penkus Corzo, R.Ph., MBA, to its Board of Directors, effective November 1, 2025.
Penkus Corzo brings over 30 years of global leadership in R&D, clinical trials, regulatory approvals, commercialization, and corporate strategy. She most recently served as President and COO at bit.bio Ltd, and has held senior leadership positions at Takeda Ventures, Sanofi Genzyme, Hoffmann-La Roche, Eli Lilly, and Syndax Pharmaceuticals.
Marker Therapeutics is focused on developing next-generation T cell-based immunotherapies. The company’s president and CEO, Juan Vera, M.D., believes Penkus Corzo’s oncology background and commercialization experience will be invaluable as the company advances its clinical and corporate objectives, especially with lead asset MT-601. The company has also strategically strengthened its Board of Directors to support the critical next phase.
The MAR-T cell platform represents a next-generation approach in cell therapy with the potential to offer improved clinical outcomes to patients with limited therapeutic options.
The multi-antigen recognizing (MAR) T cell platform is a novel, non-genetically modified cell therapy approach that selectively expands tumor-specific T cells from a patient’s/donor’s blood capable of recognizing a broad range of tumor antigens. Unlike other T cell therapies, MAR-T cells allow the recognition of hundreds of different epitopes within up to six tumor-specific antigens, thereby reducing the possibility of tumor escape.
Contact:
Marker Therapeutics, Inc.
+1 (713) 400-6400
investor.relations@markertherapeutics.com
Source: Marker Therapeutics, Inc.
